Gene · 442900
Papers2,392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,392
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Novel circ_0075829/miR-326/GOT1 ceRNA Crosstalk Regulates the Malignant Phenotypes and Drug Sensitivity of Gemcitabine-Resistant Pancreatic Cancer Cells. | J Biochem Mol Toxicol | 2025 | 39692397 | PubTator, text mining | PubMed |
| Knockdown of HOTAIR Alleviates High Glucose-Induced Apoptosis and Inflammation in Retinal Pigment Epithelial Cells. | Appl Biochem Biotechnol | 2025 | 39607470 | PubTator, text mining | PubMed |
| CircPCNXL2 promotes preeclampsia progression by suppressing trophoblast cell proliferation and invasion via miR-487a-3p/interferon regulatory factor 2 axis. | J Hypertens | 2025 | 39466687 | PubTator, text mining | PubMed |
| Silencing of circRPPH1 Inhibits the Progression of Non-Small-Cell Lung Cancer Through miR-326/ERBB4 Signal Axis. | Biochem Genet | 2025 | 38776052 | PubTator, text mining | PubMed |
| LncRNA DNM1P35 sponges hsa-mir-326 to promote ovarian cancer progression. | Sci Rep | 2024 | 39732940 | PubTator, text mining | PubMed |
| MicroRNA networks in prolactinoma tumorigenesis: a scoping review. | Cancer Cell Int | 2024 | 39702128 | PubTator, text mining | PubMed |
| LINC01270 Regulates the NF-κB-Mediated Pro-Inflammatory Response via the miR-326/LDOC1 Axis in THP-1 Cells. | Cells | 2024 | 39682774 | PubTator, text mining | PubMed |
| Hsa_circRNA_000166 accelerates breast cancer progression via the regulation of the miR-326/ELK1 and miR-330-5p/ELK1 axes. | Ann Med | 2024 | 39529543 | PubTator, text mining | PubMed |
| Circ_0005397/miR-326 and linc00152/miR-216b share the signaling pathway of PDK2 to promote pancreatic adenocarcinoma oncogenesis. | Arch Med Sci | 2024 | 39439674 | PubTator, text mining | PubMed |
| miR-326 overexpression inhibits colorectal cancer cell growth and proteasome activity by targeting PNO1: unveiling a novel therapeutic intervention strategy. | Sci Rep | 2024 | 39414903 | PubTator, text mining | PubMed |
| A comprehensive in silico analysis and experimental validation of miRNAs capable of discriminating between lung adenocarcinoma and squamous cell carcinoma. | Front Genet | 2024 | 39381140 | PubTator, text mining | PubMed |
| Bioinformatic Exploration of Circulating microRNAs Related to Functional Outcomes in Patients With Acute Ischemic Stroke: An Exploratory Prospective Study. | Cureus | 2024 | 39310540 | PubTator, text mining | PubMed |
| A Pilot Study of Saliva MicroRNA Signatures in Children with Moderate-to-Severe Traumatic Brain Injury. | J Clin Med | 2024 | 39274278 | PubTator, text mining | PubMed |
| Specific microRNA Profile Associated with Inflammation and Lipid Metabolism for Stratifying Allergic Asthma Severity. | Int J Mol Sci | 2024 | 39273372 | PubTator, text mining | PubMed |
| Identification of autophagy-related signatures in doxorubicin-induced cardiotoxicity. | Toxicol Appl Pharmacol | 2024 | 39218162 | PubTator, text mining | PubMed |
| Identification of Immune Gene Signature Associated with T Cells and Natural Killer Cells in Type 1 Diabetes. | Diabetes Metab Syndr Obes | 2024 | 39139741 | PubTator, text mining | PubMed |
| Retraction Note: Circular RNA hsa_circ_0000517 modulates hepatocellular carcinoma advancement via the miR-326/SMAD6 axis. | Cancer Cell Int | 2024 | 39123177 | PubTator, text mining | PubMed |
| LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression. | Mol Cell Probes | 2024 | 39074568 | PubTator, text mining | PubMed |
| Expression and Functional Analysis of Immuno-Micro-RNAs mir-146a and mir-326 in Colorectal Cancer. | Curr Issues Mol Biol | 2024 | 39057062 | PubTator, text mining | PubMed |
| Analysis of Th17 cell population and expression of microRNA and factors related to Th17 in patients with premature ovarian failure. | J Reprod Immunol | 2024 | 39053202 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/442900/papers?page=5